Incorporating target heterogeneity in drug design (Q34528450)

2 August 2017

1 reference

title

Incorporating target heterogeneity in drug design (English)

1 reference

2 August 2017

0 references

0 references

1 reference

Adrian Velazquez-campoy

object named as

Adrian Velazquez-Campoy

0 references

Velazquez-Campoy A

1 reference

2 August 2017

Freire E

series ordinal

1 reference

2 August 2017

Ernesto Freire

series ordinal

0 references

publication date

1 January 2001

1 reference

Journal of Cellular Biochemistry

2 August 2017

2001

0 references

published in

1 reference

2 August 2017

volume

Suppl 37

1 reference

2 August 2017

0 references

issue

S37

0 references

page(s)

82-88

1 reference

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors

2 August 2017

cites work

1 reference

Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities

21 January 2018

1 reference

Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase

21 January 2018

1 reference

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

21 January 2018

1 reference

Structure-based calculation of the equilibrium folding pathway of proteins. Correlation with hydrogen exchange protection factors.

21 January 2018

1 reference

Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases

21 January 2018

1 reference

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease

21 January 2018

1 reference

The Key–Lock Theory and the Induced Fit Theory

21 January 2018

1 reference

Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance

21 January 2018

1 reference

Thermodynamic Basis of Resistance to HIV-1 Protease Inhibition: Calorimetric Analysis of the V82F/I84V Active Site Resistant Mutant†

21 January 2018

1 reference

The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design

21 January 2018

1 reference

Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes

21 January 2018

1 reference

JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.

21 January 2018

1 reference

21 January 2018

1 reference

The structural stability of the HIV-1 protease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCB.10068

0 references

1 reference